Phage therapy to treat cystic fibrosis Burkholderia cepacia complex lung infections: perspectives and challenges

Research output: Contribution to journalReview articlepeer-review

3 Citations (Web of Science)

Abstract

Burkholderia cepacia complex is a cause of serious lung infections in people with cystic fibrosis, exhibiting extremely high levels of antimicrobial resistance. These infections are difficult to treat and are associated with high morbidity and mortality. With a notable lack of new antibiotic classes currently in development, exploring alternative antimicrobial strategies for Burkholderia cepacia complex is crucial. One potential alternative seeing renewed interest is the use of bacteriophage (phage) therapy. This review summarises what is currently known about Burkholderia cepacia complex in cystic fibrosis, as well as challenges and insights for using phages to treat Burkholderia cepacia complex lung infections.

Original languageEnglish
Article number1476041
Number of pages12
JournalFrontiers in Microbiology
Volume15
Early online date18 Oct 2024
DOIs
Publication statusPublished - 2024

Fingerprint

Dive into the research topics of 'Phage therapy to treat cystic fibrosis Burkholderia cepacia complex lung infections: perspectives and challenges'. Together they form a unique fingerprint.

Cite this